# Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

> **NCT05221021** · PHASE4 · RECRUITING · sponsor: **Walter Reed National Military Medical Center** · enrollment: 152 (estimated)

## Conditions studied

- Overactive Bladder Syndrome

## Interventions

- **DRUG:** Vaginal estrogen
- **DRUG:** Mirabegron 50 MG [Myrbetriq]

## Key facts

- **NCT ID:** NCT05221021
- **Lead sponsor:** Walter Reed National Military Medical Center
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-01
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-01-30
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05221021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05221021, "Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05221021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*